TheraRadar
Data updated: May 26, 2026

AMBIEN CR (zolpidem tartrate)

Sleep Approved 2005-09-02

Ambien CR is an extended-release medication used for the short-term management of insomnia. It helps patients who have trouble falling asleep as well as those who struggle to stay asleep during the night. This treatment is prescribed to improve sleep onset and reduce the amount of time spent awake after initially drifting off.

Source: FDA Label • COSETTE

How AMBIEN CR Works

This drug works by binding to the benzodiazepine site of specific GABA A receptors in the brain. This action increases the frequency of chloride channel opening, which inhibits neuronal excitation to help facilitate sleep.

2
Indications
--
Phase 3 Trials
20
Years on Market

Details

Status
Prescription
First Approved
2005-09-02
Routes
ORAL
Dosage Forms
TABLET, EXTENDED RELEASE

Companies

Active Ingredient: ZOLPIDEM TARTRATE

AMBIEN CR Approval History

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
38 FDA actions from 2005 to 2022 · 1 indication expansions
Feb 2022 SUPPL
Label · Labeling
Aug 2019 SUPPL
Label · Labeling
Feb 2019 SUPPL
Label · Labeling

What AMBIEN CR Treats

1 indications

AMBIEN CR is approved for 1 conditions since its original approval in 2005. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Insomnia
Source: FDA Label

AMBIEN CR Boxed Warning

COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of AMBIEN CR. Some of these events may result in serious injuries, including death. Discontinue AMBIEN CR immediately if a patient experiences a complex sleep behavior [see Contraindications (4) and Warnings and Precautions (5.1) ]. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning. Comple...

AMBIEN CR Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 16 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to AMBIEN CR

3 of 17

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AMBIEN
ZOLPIDEM TARTRATE
1 shared
COSETTE
Shared indications:
BELSOMRA
SUVOREXANT
1 shared
Merck
Shared indications:
DAYVIGO
LEMBOREXANT
1 shared
EISAI INC
Shared indications:
📋

Clinical Trial Registry

4 trials
Trial Sponsor ID Phase Status Title
NCT03774810 R01 results posted 831801 R01AG054521-01A1 Ph 4 completed Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
NCT02783729 SUNRISE 1 results posted E2006-G000-304 2015-004347-39 Ph 3 completed Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
NCT03307005 results posted IRB00142395 Ph 4 completed Improving Sleep Quality in Heart Failure
NCT00683436 NG2-73-205 Ph 2 terminated Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

AMBIEN CR FDA Label Details

Indications & Usage

FDA Label (PDF)

AMBIEN CR is indicated for the treatment of Insomnia.

⚠️ BOXED WARNING

WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of AMBIEN CR. Some of these events may result in serious injuries, including death. Discontinue AMBIEN CR immediately if a p...

Track AMBIEN CR with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.